Shares of TeamHealth Holdings Inc (NYSE:TMH) have earned a consensus rating of “Buy” from the eighteen brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and ten have given a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $54.00.
TeamHealth Holdings (NYSE:TMH) traded down 0.55% on Wednesday, reaching $43.02. 600,736 shares of the company’s stock traded hands. The firm has a market capitalization of $3.16 billion and a P/E ratio of 38.41. The stock has a 50-day moving average of $40.22 and a 200 day moving average of $48.82. TeamHealth Holdings has a 52 week low of $33.15 and a 52 week high of $70.21.
TeamHealth Holdings (NYSE:TMH) last released its quarterly earnings results on Monday, February 22nd. The company reported $0.61 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.62 by $0.01. The business had revenue of $979.60 million for the quarter, compared to the consensus estimate of $982.09 million. During the same quarter in the prior year, the company earned $0.56 earnings per share. TeamHealth Holdings’s revenue was up 23.9% compared to the same quarter last year. On average, equities analysts expect that TeamHealth Holdings will post $2.87 EPS for the current fiscal year.
Several equities research analysts have issued reports on the stock. Jefferies Group reaffirmed a “buy” rating and set a $80.00 price target on shares of TeamHealth Holdings in a research note on Monday, November 30th. Goldman Sachs started coverage on shares of TeamHealth Holdings in a report on Monday, November 30th. They set a “neutral” rating and a $63.00 price objective on the stock. Mizuho started coverage on shares of TeamHealth Holdings in a report on Thursday, December 3rd. They set a “neutral” rating and a $59.00 price objective on the stock. Canaccord Genuity reiterated a “buy” rating and set a $75.00 price objective (up from $73.00) on shares of TeamHealth Holdings in a report on Wednesday, December 9th. Finally, Robert W. Baird lowered shares of TeamHealth Holdings from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $70.00 to $49.00 in a report on Monday, December 14th.
Team Health Holdings, Inc (NYSE:TMH) is a provider of outsourced healthcare professional staffing and administrative services to hospitals and other healthcare providers in the United States. The Company provides services through two operating segments: Healthcare Staffing and Other Services.